Insmed, Inc.
INSM
$98.60
-2.85%
Insmed Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, with its portfolio organized around Respiratory, Immunology and Inflammation, and Neuro and Other Rare therapeutic areas. The company distinguishes itself through a diversified pipeline spanning multiple modalities, including gene therapy and AI-driven protein engineering, and has two commercial products, Arikayce and Brinsupri, in the respiratory space. Currently, investor attention is centered on the company's revenue growth trajectory, driven by Arikayce and Brinsupri sales, and the clinical progress of key pipeline assets like brensocatib, which could unlock significant value. The stock has experienced substantial volatility over the past year, reflecting both optimism around pipeline catalysts and concerns about ongoing losses and competitive dynamics.…
INSM
Insmed, Inc.
$98.60
Related headlines
Investment Opinion: Should I buy INSM Today?
Rating: Hold. The thesis is that Insmed's explosive revenue growth and strong analyst support are offset by deep losses, extreme valuation, and technical weakness, making the risk/reward balanced at current levels. The analyst consensus is Strong Buy with an average target of $196.18, implying 83.5% upside, but the stock's downtrend and cash burn warrant caution. Supporting evidence: (1) Revenue grew 229.6% YoY to $305.96M in Q1 2026, showing strong commercial traction. (2) Gross margin improved to 83.8% from 77.1% a year ago. (3) The forward PS of ~6.09x is near the biotech industry average, suggesting the current price already discounts significant future revenue. (4) The average analyst target of $196.18 offers 83.5% upside, but the stock's 3-month decline of 20.9% indicates market skepticism. Risks & Conditions: The biggest risks are (1) continued cash burn requiring dilutive financing, (2) pipeline setbacks for brensocatib, and (3) failure to achieve profitability. This Hold would upgrade to Buy if the stock breaks above its 50-day moving average and revenue growth sustains above 50% YoY, or downgrade to Sell if free cash flow deteriorates further or the stock breaks below $90.39. Valuation verdict: The stock is fairly valued on a forward PS basis but overvalued on trailing metrics relative to history and peers.
Sign up to view all
INSM 12-Month Price Forecast
The outlook for INSM over the next 12 months is balanced. The company's revenue growth is impressive, but the path to profitability remains uncertain. The forward PS suggests the stock is fairly valued if growth continues, but the trailing PS highlights the risk of multiple compression. The strong analyst consensus provides a floor, but the technical downtrend and cash burn are headwinds. A neutral stance is warranted until there is clearer evidence of margin improvement or pipeline success. An upgrade to bullish would require sustained revenue growth above 100% YoY and positive free cash flow trajectory; a downgrade to bearish would follow a pipeline failure or significant deceleration in revenue.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $196.18 and implied upside of +99.0% versus the current price.
Average Target
$196.18
0 analysts
Implied Upside
+99.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $243
Analyst target range
Insmed is covered by 22 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.22 on a 1-5 scale). The average target price is $196.18, implying approximately 83.5% upside from the current price of $106.92. The distribution shows no sell ratings, indicating strong bullish sentiment. The high target of $243.00 suggests potential for 127% upside, likely assuming successful pipeline execution and significant revenue growth from brensocatib and other programs. The low target of $140.00 still implies 30.9% upside, reflecting a base case where current products continue to grow but pipeline risks materialize. Recent ratings from major firms like Wells Fargo, Guggenheim, and JP Morgan have maintained Overweight/Buy ratings, with no downgrades, reinforcing positive sentiment. The wide spread between low and high targets ($140 to $243) indicates high uncertainty around the company's future, typical for a biotech with a binary pipeline event. The strong consensus and high upside potential suggest analysts are optimistic about Insmed's growth story, but the stock's recent decline may reflect market skepticism about near-term profitability.
Bulls vs Bears: INSM Investment Factors
Insmed presents a high-risk, high-reward profile. The bull case rests on explosive revenue growth (229.6% YoY), strong analyst support (83.5% upside to average target), and improving gross margins (83.8%). However, the bear case is equally compelling: deep losses (net margin -53.5%), massive cash burn (TTM FCF -$951.6M), and an extreme trailing PS of 61.31x. The stock's technical downtrend and high short ratio (3.2) add to the caution. The single most important tension is whether the company can achieve profitability before running out of cash or needing dilutive financing. If revenue growth sustains and margins continue to improve, the stock could re-rate higher; if not, the valuation could compress further.
Bullish
- Revenue growth accelerating: Q1 2026 revenue surged 229.6% YoY to $305.96M, driven by Arikayce and Brinsupri sales. This rapid top-line expansion signals strong commercial execution and market adoption.
- Analyst consensus Strong Buy: 22 analysts rate INSM a Strong Buy with a mean target of $196.18, implying 83.5% upside from $106.92. No sell ratings exist, reflecting broad institutional optimism.
- Improving gross margins: Gross margin improved to 83.8% in Q1 2026 from 77.1% a year ago, indicating better cost management and product mix. Higher margins support the path to profitability.
- Pipeline catalyst potential: Key asset brensocatib could unlock significant value if clinical data is positive. The high analyst target of $243 implies 127% upside, reflecting pipeline optionality.
Bearish
- Deeply unprofitable with cash burn: Net loss was $163.56M in Q1 2026, and TTM free cash flow was -$951.64M. The company relies on external financing, as seen by $30.31M in equity issued in Q1.
- Extreme trailing PS valuation: Trailing PS of 61.31x is extremely high vs. biotech peers (5-10x), implying the market is pricing in aggressive growth that may not materialize.
- Stock in sustained downtrend: The stock is down 20.9% over 3 months and 31.6% over 6 months, underperforming the S&P 500 by 24.4% and 38.8% respectively. Technical weakness persists.
- Negative ROE and operating margin: ROE is -172.8% and operating margin is -194%, reflecting severe operational inefficiency. The company is burning cash to generate revenue.
INSM Technical Analysis
Insmed's stock is in a sustained downtrend, with a 1-year price change of +3.28% masking a significant decline from its 52-week high. The current price of $106.92 sits at 50.2% of its 52-week range ($90.39 to $212.75), indicating it is closer to the low end, which could suggest a value opportunity or a falling knife depending on fundamental catalysts. The stock has underperformed the S&P 500 significantly over the past year, with a relative strength of -13.19%, highlighting persistent selling pressure. Over the past 3 months, the stock has declined 20.9%, while the S&P 500 gained 3.5%, showing severe relative weakness. However, the 1-month price change of +3.34% versus the S&P 500's +0.78% suggests a short-term bounce, potentially signaling a temporary reprieve or early reversal attempt. This divergence between the 1-month positive momentum and the 3-month negative trend could indicate a short-term mean reversion, but the overall downtrend remains intact. The 52-week low of $90.39 provides key support, while the 52-week high of $212.75 is a major resistance level. A break above $212.75 would signal a trend reversal, while a drop below $90.39 could accelerate losses. With a beta of 0.778, Insmed is less volatile than the market, meaning its downtrend has been more orderly but still persistent, and any recovery may be slower relative to broader market moves.
Beta
0.78
0.78x market volatility
Max Drawdown
-56.5%
Largest decline past year
52-Week Range
$90-$213
Price range past year
Annual Return
-8.1%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | -7.9% | +0.2% |
| 3m | -26.0% | +3.7% |
| 6m | -37.1% | +8.0% |
| 1y | -8.1% | +18.2% |
| ytd | -44.3% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Insmed's revenue has grown strongly, with Q1 2026 revenue of $305.96 million representing a 229.6% year-over-year increase from $92.82 million in Q1 2025, driven by commercial product sales. However, the company remains unprofitable, with a net loss of $163.56 million in Q1 2026, though this loss narrowed from $256.58 million in Q1 2025. The gross margin improved to 83.8% in Q1 2026 from 77.1% a year earlier, indicating better cost management, but operating expenses remain high, with R&D of $209.49 million and SG&A of $247.26 million in Q1 2026. The net margin was -53.5% in Q1 2026, improving from -276.4% in Q1 2025, but still deeply negative. Insmed's balance sheet shows a debt-to-equity ratio of 1.04, indicating moderate leverage, and a current ratio of 3.83, suggesting ample liquidity. However, free cash flow was negative $226.22 million in Q1 2026, and the trailing twelve-month free cash flow was -$951.64 million, meaning the company is burning cash to fund operations and growth. Return on equity is deeply negative at -172.8%, reflecting persistent losses relative to shareholder equity. The company has raised capital through equity offerings, as seen in common stock issued of $30.31 million in Q1 2026, indicating reliance on external financing.
Quarterly Revenue
$305964000.0B
2026-03
Revenue YoY Growth
+229.6%
YoY Comparison
Gross Margin
83.8%
Latest Quarter
Free Cash Flow
$-951635000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
Since Insmed has negative net income (net loss of $163.56 million in Q1 2026), the price-to-earnings ratio is not meaningful. Therefore, we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 61.31x, while the forward PS ratio (based on estimated revenue of $6.11 billion) is approximately 6.09x, implying the market expects massive revenue growth. The wide gap between trailing and forward PS suggests aggressive growth expectations. Compared to the biotechnology industry average PS ratio (typically around 5-10x for profitable biotechs, but higher for high-growth names), Insmed's trailing PS of 61.31x is extremely high, reflecting a premium for its revenue growth and pipeline potential. However, the forward PS of ~6.09x is more in line with industry norms, indicating that the current price already discounts substantial future revenue. Historically, Insmed's PS ratio has ranged from around 35x to 215x over the past five years. The current trailing PS of 61.31x is near the lower end of this range, suggesting the stock may be relatively cheap compared to its own history, but this could also reflect deteriorating growth prospects or increased risk. The PB ratio of 50.31x is also elevated, typical for biotech firms with negative earnings.
PE
-27.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Insmed's primary financial risk is its persistent unprofitability and cash burn. The company reported a net loss of $163.56M in Q1 2026, and TTM free cash flow was -$951.64M. With a debt-to-equity ratio of 1.04, leverage is moderate, but the negative ROE of -172.8% indicates that shareholder equity is being eroded. The company relies on equity issuance to fund operations, as seen by $30.31M in common stock issued in Q1 2026. If revenue growth decelerates or margins fail to improve, the company may need to raise additional capital at unfavorable terms, diluting existing shareholders. Market & Competitive Risks: The stock's trailing PS of 61.31x is far above the biotech industry average of 5-10x, leaving it vulnerable to valuation compression if growth disappoints. The stock has a beta of 0.778, meaning it is less volatile than the market, but its recent 3-month decline of 20.9% versus the S&P 500's gain of 3.5% shows severe relative weakness. Competitive risks include pipeline setbacks for brensocatib or other candidates, which could erase the premium embedded in the forward PS of ~6.09x. The high short ratio of 3.2 suggests significant bearish positioning. Worst-Case Scenario: A realistic worst-case scenario involves a pipeline failure (e.g., brensocatib clinical trial miss) combined with slowing revenue growth and continued cash burn. In this scenario, the stock could fall to its 52-week low of $90.39, representing a 15.5% decline from the current price of $106.92. If the company needs to raise capital at depressed prices, further downside to $80 or below is possible, implying a loss of up to 25% or more.
FAQ
The key risks are: (1) Financial risk: The company is unprofitable with a net loss of $163.56M in Q1 2026 and negative free cash flow of -$951.64M TTM, requiring external financing that could dilute shareholders. (2) Pipeline risk: The stock's upside depends heavily on brensocatib's success; a clinical failure could erase the premium. (3) Valuation risk: The trailing PS of 61.31x leaves little room for error; any growth deceleration could cause a sharp de-rating. (4) Technical risk: The stock is in a downtrend, down 20.9% over 3 months, with a high short ratio of 3.2, indicating bearish sentiment.
The 12-month forecast is mixed. The bull case (25% probability) sees the stock reaching $180-$243, driven by positive pipeline data and sustained revenue growth. The base case (50% probability) targets $140-$180, assuming continued growth but persistent losses. The bear case (25% probability) sees the stock falling to $90-$140, due to pipeline setbacks or slowing growth. The most likely scenario is the base case, with the stock trading near the average analyst target of $196.18, but the wide range reflects high uncertainty.
INSM's valuation is mixed. The trailing PS ratio of 61.31x is extremely high compared to the biotech industry average of 5-10x, suggesting overvaluation. However, the forward PS ratio of ~6.09x, based on estimated revenue of $6.11B, is in line with industry norms, implying the stock is fairly valued if the company achieves those revenue targets. Historically, the stock's PS has ranged from 35x to 215x over five years, so the current trailing PS is near the lower end of its own history. The market is pricing in aggressive growth, and any disappointment could lead to multiple compression.
INSM is a high-risk, high-reward stock. The analyst consensus is Strong Buy with an average target of $196.18, implying 83.5% upside from $106.92. However, the company is deeply unprofitable with a net loss of $163.56M in Q1 2026 and TTM free cash flow of -$951.64M. The stock is in a downtrend, down 20.9% over 3 months. For aggressive investors with a long-term horizon and tolerance for volatility, it could be a good buy if they believe in the revenue growth story and pipeline. For conservative investors, the risks of cash burn and valuation compression make it less suitable.
INSM is more suitable for long-term investment given its pre-profitability stage and reliance on pipeline catalysts. The stock has a beta of 0.778, indicating lower volatility than the market, but its 3-month decline of 20.9% shows significant short-term risk. The company does not pay a dividend. For long-term investors (3-5 years), the potential for revenue growth and pipeline success could yield substantial returns. Short-term trading is risky due to the downtrend and high short ratio. A minimum holding period of 2-3 years is recommended to allow pipeline catalysts to materialize.